



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/560,385-Conf. #3846
				Filing Date	January 12, 2007
				First Named Inventor	Michael G. Orchard
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	A0345.0021

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA	EP-0 536 402	04-14-1993	Nippon Shinyaku Company		✓
	BB	EP 0 698 012 (WO-94/26714)	11-24-1994	G.D. Searle & Co et al.		✓

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	GIULIO ALESSANDRI, ET AL., "Angiogenic and Angiostatic Microenvironment in Tumors," <i>Anct Onco.</i> (1997), 36(4), pp. 383-387	
	CB	ANTHONY LUCCI, ET AL., "Glucosylceramide: a Marker for Multiple-Drug Resistant Cancers," <i>Anticancer Res.</i> (1998), 18(1B), pp. 475-480	
	CC	PETER DE MAN, ET AL., "Bacterial adherence as a virulence factor in urinary tract infection," <i>APMIS</i> (1990), 98(12), pp. 1053-1060	
	CD	KM NICHOLSON, ET AL., "Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase," <i>Br. J. Cancer</i> (1999), 81(3), pp. 423-430	
	CE	GUNNAR C. HANSSON, ET AL., "A novel approach to the study of glycolipid receptors for viruses," <i>FEBS Lett.</i> (1984), 170(1), pp. 15-18	
	CF	VICTOR JIMENEZ-LUCHO, ET AL., "Cryptococcus neoformans, Candida albicans, and Other Fungi Bind Specifically to the Glycosphingolipid Lactosylceramide (Galβ1-4Glcβ1-1Cer), a Possible Adhesion Receptor for Yeasts," <i>Infect. Immun.</i> (1990), 58(7), pp. 2085-2090	
	CG	YAAKOV LAVIE, ET AL., "Agents that Reverse Multidrug Resistance, Tamoxifen, Verapamil, and Cyclosporin A, Block Glycosphingolipid Metabolism by Inhibiting Ceramide Glycosylation in Human Cancer Cells," <i>J. Biol. Chem.</i> (1997) 272(3), pp. 1682-1687	
	CH	YONG-YU LIU, ET AL., "Uncoupling Ceramide Glycosylation of Transfection of Glucosylceramide Synthase Antisense Reverses Adriamycin Resistance," <i>J. Biol. Chem.</i> (2000), 275(10), pp. 7138-7143	
	CI	RUIXIANG LI, ET AL., "Cellular Gangliosides Promote Growth Factor-induced Proliferation of Fibroblasts," <i>J. Biol. Chem.</i> (2000), 275(44), pp. 34213-34223	
	CJ	IVAN Z. ZADOR, ET AL., "A Role for Glycosphingolipid Accumulation in the Renal Hypertrophy of Streptozotocin-induced Diabetes Mellitus," <i>Clin. Invest.</i> (1993), 91(3), pp. 797-903	
	CK	AKIRA ABE, ET AL., "Reduction of globotriaosylceramide in Fabry disease mice by substrate	
Examiner Signature			Date Considered

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/560,385-Conf. #3846
				Filing Date	January 12, 2007
				First Named Inventor	Michael G. Orchard
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	A0345.0021

		deprivation," J. Clin. Invest. (2000), 105(11), pp. 1563-1571	
CL		ROBERT MCKALLIP, ET AL., "Tumor Gangliosides Inhibit the Tumor-Specific Immune Response," J. Immuno. (1999), 163(7), pp. 3718-3726	
CM		MAJLIS SVENSSON, ET AL., "Carbohydrate Receptor Depletion as an Antimicrobial Strategy for Prevention of Urinary Tract Infection," J. Infect. Dis. (2001), suppl. 70-73, p. 183	
CN		SUBROTO CHATTERJEE, ET AL., "Role of lactosylceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease," J. Lipid. Res. (1996), 37(6), pp. 1334-1344	
CO		TIMOTHY COX, ET AL., "Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis," Lancet (2000), 355(9214), pp. 1481-1485	
CP		N.V. PROKAZOVA, ET AL., "Gangliosides and Atherosclerosis," Lipids (1994), 29(1), pp. 1-5	
CQ		KAZUKO HANDA, ET AL., "Analysis of Glycolipid-Dependent Cell Adhesion Based on Carbohydrate-Carbohydrate Interaction," Methods Enzymol. (2000), 312, pp. 447-458	
CR		CLIFFORD A. LINGWOOD, ET AL., "Analysis of Interactions between Glycosphingolipids and Microbial Toxins," Methods Enzymol. (2000), 312, pp. 459-473	
CS		ABDERRAHIM MERZAK, ET AL., "Gangliosides Modulate Proliferation, Migration, and Invasiveness of Human Brain Tumor Cells In Vitro," Mol. Chem. Neuropathol. (1995), 24(2-3), pp. 121-135	
CT		KAI SIMONS ET AL., "Functional rafts in cell membranes," Nature (1997), 387(6633), pp. 569-572	
CU		PRAVEEN TYLE, "Ionophoretic Devices for Drug Delivery," Pharmaceutical Research (1986), 3(6), p. 318	
CV		LINDA A. GOODMAN, ET AL., "Ectopic dendrites occur only on cortical pyramidal cells containing elevated GM2 ganglioside in α -mannosidosis," Proc. Natl. Acad. Sci. USA (1991), 88(24), pp. 11330-11334	
CW		CHII-SHIARING CHEN, ET AL., "Abnormal transport along the lysosomal pathway in Mucopolipidosis, type IV disease," Proc. Natl. Acad. Sci. USA (1998), 95(11), pp. 6373-6378	
CX		MYLVAGANAM JEYAKUMAR, ET AL., "Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin," Proc. Natl. Acad. Sci. USA (1999), 96(11), pp. 6388-6393	
CY		Protective Groups in Organic Chemistry, T.W. Greene and P.G.M. Wuts, (Wiley-Interscience, New York, 2nd edition) (1991)	
CZ		FRANCES M. PLATT, ET AL., "Prevention of Lysosomal Storage in Tay-Sachs Mice Treated with N-Butyldeoxynojirimycin," Science (1997), 276(5311), pp. 428-431	
CA1		MILTON ALTER, "GM ₁ , Ganglioside for Acute Ischemic Stroke," Alter, Ann. NY Acad. Sci. (1998), 845, pp. 391-401	
CB1		LIN-PING CHOO-SMITH ET AL., "Acceleration of Amyloid Fibril Formation by Specific Binding of A β -(1-40) Peptide to Ganglioside-containing Membrane Vesicles," Biol. Chem. (1997), 272, pp 22987-22990	
CC1		FOWLER, P.A. ET AL., "Synthesis and activity towards yeast α -glucosidase of 1,5-dideoxy-1,5-imino-L-iditol (1-deoxy-L-idonojirimycin), Carbohydr. Res. (1993), 246, pp. 377-381	
CD1		FRED H. GEISLER, "Clinical Trials of Pharmacotherapy for Spinal Cord Injury," NY Acad. Sci. (1998), 845, pp. 374-381	
CE1		MEMON, R.A. ET AL., "Regulation of Glycosphingolipid Metabolism in Liver during the Acute Phase Response," J. Biol. Chem. (1999), 274(28), pp. 19707-19713	
CF1		MEMON, R.A., ET AL., "Regulation of sphingolipid and glycosphingolipid metabolism in	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/560,385-Conf. #3846
				Filing Date	January 12, 2007
				First Named Inventor	Michael G. Orchard
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	A0345.0021

		extrahepatic tissues by endotoxin," J. Lipid. Res. (2001), 42(3), pp. 452-459	
	CG1	OVERKLEEF, H.S. ET AL., "Generation of Specific Deoxynojirimycin-type Inhibitors of the Non-lysosomal Glucosylceramidase," J. Biol. Chem. (1998), 273, pp. 26522-26527	
	CH1	FRANCES M. PLATT ET AL., "N-Butyldeoxygalactonojirimycin Inhibits Glycolipid Biosynthesis but Does Not Affect N-Linked Oligosaccharide Processing," J. Biol. Chem. (1994), 269, pp. 27108-27114	
	CI1	RAO, V.S. ET AL., "Regioselective eliminations in reactions of carbohydrate derivatives with superoxide, or with borohydride in 2-propanol," Can. J. Chem. (1981), 59(2), pp. 333-338	
	CJ1	RYAN, J.L. ET AL., "Changes in Membrane Gangliosides: Differentiation of Human and Murine Monocytic Cells," Yale J. Biol. Med. (1985), 58(2), pp. 125-131	
	CK1	J.S. SCHNEIDER, "GM1 Ganglioside in the Treatment of Parkinson's Disease," Anatomy and Cell Biology, (1990), 845, pp. 363-373	
	CL1	KATSUHIKO YANAGISAWA ET AL., "GM1 ganglioside-bound amyloid β -protein ($A\beta$): A possible form of preamyloid in Alzheimer's disease," Nat. Med. (1995), 1, pp. 1062-1066	
	CM1	HERBERT C. YOHE, ET AL., "Ganglioside alterations in stimulated murine macrophages," Biochim. Biophys. Acta (1985), 818(1), pp. 81-86	
	CN1	HERBERT C. YOHE, ET AL., "Ganglioside expression in Macrophages from Endotoxin Responder and Non-Responder Mice," Immunol. (1986), 137(12), pp. 3921-3927	
	CO1	HERBERT C. YOHE ET AL., "The Presence of Sialidase-Sensitive Sialosylgangliosyl Ceramide (GM1b) in Stimulated Murine Macrophages," Immunol. (1991), 146(6), pp. 1900-1908	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--